Delphia Therapeutics
- Biotech or pharma, therapeutic R&D
Delphia Therapeutics, located in Cambridge, MA, is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer’s surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies. Delphia has made rapid progress in less than two years since inception, with potential for multiple novel and first/best-in-class development candidates in 2025. Activation Lethality is proving to be a rich new biology area, supporting a strong pipeline beyond our lead assets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}